<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112104">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643902</url>
  </required_header>
  <id_info>
    <org_study_id>ML28242</org_study_id>
    <nct_id>NCT01643902</nct_id>
  </id_info>
  <brief_title>Safety of Intravenous Thrombolytics in Stroke on Awakening</brief_title>
  <acronym>SAIL-ON</acronym>
  <official_title>Safety of Intravenous Thrombolytics in Stroke on Awakening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety of intravenous tPA in patients
      waking up with symptoms of acute stroke and presenting to the ED within 4.5 hours from
      awakening, and meeting standard criteria for treatment with IV tPA for acute stroke.

      The hypothesis is that patients that wake up with stroke symptoms may have developed the
      stroke at the time of awakening, and may be within the 4.5 hour window if they arrive to the
      ED within that time, therefore IV tPA should be safe and effective in this population.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptomatic intracerebral hemorrhage</measure>
    <time_frame>within 36 hours of treatment</time_frame>
    <description>Data on symptomatic intracerebral hemorrhage by using the ECASS 3 criteria as well as the original NINDS IV rt-PA trial criteria for comparison.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional outcome.</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluate mRankin score, NIHSS, Barthel index at 90 days. (NIHSS also collected at 24 hours)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>IV rt-PA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rt-PA</intervention_name>
    <description>IV rt-PA 0.9 mg/kg minimum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target foor to needle time of 60 minutes or less from ED arrival.</description>
    <arm_group_label>IV rt-PA</arm_group_label>
    <other_name>Activase</other_name>
    <other_name>Alteplase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater or equal to 18 years.

          -  Signs and symptoms of acute ischemic stroke.

          -  Symptoms present upon awakening.

          -  Arriving to the Emergency Department within 4.5 hours of awakening. Treatment with IV
             rt-PA must be initiated prior to 4.5hours from waking up.

          -  NIHSS &gt;3

          -  A non-contrast head CT without hemorrhage and without hypodensity more than 1/3 of
             the MCA territory; or MRI demonstrating no hemorrhage, and with a DWI lesion no
             greater than 70mL and FLAIR without a well defined hyperintense lesion that is more
             than 1/3 of the MCA territory.

          -  Pre-morbid modified Rankin score of 0 or 1.

        Exclusion Criteria:

          -  Rapidly improving deficit to an NIHSS less than 3.

          -  Sustained systolic blood pressure greater than 185mmHg or diastolic blood pressure
             greater than 110mmHg despite treatment.

          -  Glucose less than 50mg/dL.

          -  Stroke or head trauma within last 3 months.

          -  History of intracranial hemorrhage. Symptoms of subarachnoid hemorrhage.

          -  Major surgery within 14 days.

          -  GI/GU hemorrhage within 21 days.

          -  INR &gt; 1.7.

          -  Heparin within 48 hours with an elevated aPTT.

          -  Platelet count less than 100,000.

          -  Presumed septic embolus or suspicion of bacterial endocarditis.

          -  Suspicion of aortic dissection.

          -  Use of anticoagulants such as dabigatran, rivaroxaban, apixaban, enoxaparin.

          -  Pregnant or lactating women.

          -  Known allergy or sensitivity to rt-PA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor C Urrutia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor C Urrutia, MD</last_name>
    <phone>4109552228</phone>
    <email>vurruti1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Rice, RN</last_name>
    <phone>4106143460</phone>
    <email>smrice@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Katcheves, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Katcheves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victor C. Urrutia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Llinas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Llinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>July 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Victor C Urrutia, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Wake up</keyword>
  <keyword>IV tPA</keyword>
  <keyword>Thrombolytic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrinolytic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
